Efficacy and Safety of Combined PD-1 Inhibitor with Induction Chemotherapy Followed by IMRT Plus Nimotuzumab in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Analysis [Corrigendum]

Chen K, Huang X, Chen J, Zhang S. Onco Targets Ther. 2025;18:283–296. The authors have advised that Table 1 on page 287 is incorrect. The Characteristics “Sintilimab” and “Toripalimab” listed in the PD-1 inhibitors section are interchanged. The correct Table 1 is as follows. Table 1 Baseline characteristics of patients The authors apologize for the error.